<?xml version='1.0' encoding='utf-8'?>
<document id="26392756"><sentence text="Potential drug-drug interactions in Alzheimer patients with behavioral symptoms." /><sentence text="The use of multi drug regimens among the elderly population has increased tremendously over the last decade although the benefits of medications are always accompanied by potential harm, even when prescribed at recommended doses" /><sentence text=" The elderly populations are particularly at an increased risk of adverse drug reactions considering comorbidity, poly-therapy, physiological changes affecting the pharmacokinetics and pharmacodynamics of many drugs and, in some cases, poor compliance due to cognitive impairment and/or depression" /><sentence text=" In this setting, drug-drug interaction may represent a serious and even life-threatening clinical condition" /><sentence text=" Moreover, the inability to distinguish drug-induced symptoms from a definitive medical diagnosis often results in addition of yet another drug to treat the symptoms, which in turn increases drug-drug interactions" /><sentence text=" Cognitive enhancers, including acetylcholinesterase inhibitors and memantine, are the most widely prescribed agents for Alzheimer's disease (AD) patients"><entity charOffset="68-77" id="DDI-PubMed.26392756.s6.e0" text="memantine" /></sentence><sentence text=" Behavioral and psychological symptoms of dementia, including psychotic symptoms and behavioral disorders, represent noncognitive disturbances frequently observed in AD patients" /><sentence text=" Antipsychotic drugs are at high risk of adverse events, even at modest doses, and may interfere with the progression of cognitive impairment and interact with several drugs including anti-arrhythmics and acetylcholinesterase inhibitors" /><sentence text=" Other medications often used in AD patients are represented by anxiolytic, like benzodiazepine, or antidepressant agents"><entity charOffset="81-95" id="DDI-PubMed.26392756.s9.e0" text="benzodiazepine" /></sentence><sentence text=" These agents also might interfere with other concomitant drugs through both pharmacokinetic and pharmacodynamic mechanisms" /><sentence text=" In this review we focus on the most frequent drug-drug interactions, potentially harmful, in AD patients with behavioral symptoms considering both physiological and pathological changes in AD patients, and potential pharmacodynamic/pharmacokinetic drug interaction mechanisms" /><sentence text=" " /></document>